Clinical Trials Logo
  1. Home
  2. Mucosal Melanoma
  3. NCT05420324

A Study to Assess YH003 in Combination With Pebolizumab and Albumin Paclitaxel Injection in Subjects With Unresectable/Metastatic Mucosal Melanoma

Mucosal Melanoma Clinical Trial

Official title:
A Multicenter, Single-arm, Open-label Phase II Study to Evaluate the Efficacy and Safety of YH003 in Combination With Pebolizumab and Albumin Paclitaxel in First-line Treatment of Patients With Unresectable/Metastatic Mucosal Melanoma

Clinical Trial Summary

This study is a multicenter, single-arm, open-label phase II study to assess the efficacy and safety of YH003 in combination with pembrolizumab and nab-paclitaxel in the first-line treatment of patients with unresectable/metastatic mucosal melanoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05420324
Study type Interventional
Source Eucure (Beijing) Biopharma Co., Ltd
Contact
Status Recruiting
Phase Phase 2
Start date June 13, 2022
Completion date September 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT01961115 - Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Phase 2
Active, not recruiting NCT03241186 - Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma Phase 2
Withdrawn NCT05482074 - Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 Phase 2
Completed NCT02858869 - Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases Phase 1
Completed NCT04551352 - A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas Phase 1
Active, not recruiting NCT03033576 - Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma Phase 2
Terminated NCT01166126 - Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV Phase 2
Completed NCT02158520 - Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery Phase 2
Withdrawn NCT03220009 - Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Phase 2
Recruiting NCT05628883 - Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma Phase 1
Active, not recruiting NCT03178123 - The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery Phase 2
Recruiting NCT04462965 - Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study Phase 2
Recruiting NCT04830124 - Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6 Phase 2
Not yet recruiting NCT06424626 - A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma Phase 1
Completed NCT00085189 - Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma Phase 2
Recruiting NCT05384496 - Axitinib and Nivolumab for the Treatment of Mucosal Melanoma Phase 2
Recruiting NCT06319196 - Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma Phase 2
Completed NCT02126579 - Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists Phase 1/Phase 2
Not yet recruiting NCT05545969 - Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma Phase 2
Recruiting NCT03986515 - Apatinib Plus SHR1210 in Advanced Mucosal Melanoma Phase 2